Esophageal Squamous Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Esophageal Squamous Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Loqtorzi (toripalimab) — Topalliance Biosciences Europe Limited
EMA authorised Loqtorzi (toripalimab) for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2026-07-22Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) [Phase 3]
Phase 3 trial examining pembrolizumab plus chemoradiation versus placebo in esophageal cancer has completed.
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus lenvatinib and chemotherapy in metastatic esophageal squamous cell carcinoma has completed with …
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Results: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus lenvatinib plus chemotherapy in metastatic esophageal squamous cell carcinoma completed with pos…
-
EMA approval · 2026-07-13EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-01EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma [Phase 3]
A Phase 3 trial evaluating QLC5508 versus standard chemotherapy in pretreated advanced or metastatic esophageal squamous cell carcinoma is c…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
A retrospective IPTW-adjusted analysis compares nab-paclitaxel versus paclitaxel in neoadjuvant immunochemotherapy for esophageal squamous c…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial evaluating Ifinatamab Deruxtecan in patients with advanced esophageal squamous cell carcinoma; the study …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma [NA]
A clinical trial from Fudan University is evaluating TPF-based concurrent chemoradiotherapy with immunotherapy for locally advanced esophage…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma [Phase 2]
Phase 2 neoadjuvant trial evaluating Ivonescimab (AK112) plus chemotherapy in patients with resectable esophageal squamous cell carcinoma; t…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
A clinical trial is evaluating tislelizumab plus chemotherapy as conversion therapy for unresectable locally advanced esophageal squamous ce…
-
EMA approval · 2026-04-22EMA Authorised: Loqtorzi (toripalimab) — Topalliance Biosciences Europe Limited
Loqtorzi (toripalimab) has been authorised in the European Union for nasopharyngeal carcinoma and esophageal squamous cell carcinoma. It is …
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors [Phase 1]
This first-in-human Phase 1 trial update reports ALX2004 for advanced or metastatic solid tumors and notes that the study is currently recru…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma [Phase 2]
A Phase 2 clinical trial evaluating JS212 combination therapy for advanced esophageal squamous cell carcinoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC [Phase 3]
A Phase 3 trial evaluating consolidation with toripalimab plus capecitabine after chemoradiotherapy in esophageal squamous cell carcinoma is…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma [Phase 2]
Phase II clinical trial evaluating safety and efficacy of tislelizumab in elderly patients with advanced esophageal squamous cell carcinoma …
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of Sigvotatug Vedotin in Advanced Solid Tumors [Phase 1]
Phase 1 study of Sigvotatug Vedotin in advanced solid tumors is currently recruiting. The trial targets multiple indications, including non-…
-
CLINICAL_TRIALS other · 2026-04-20Clinical Trial Update: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors [Phase 1]
Clinical trial update for PF-08046054/SGN-PDL1V in advanced solid tumors shows a Phase 1 study is currently recruiting across multiple indic…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy [Phase 3]
Phase 3 study evaluating atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma after definitive chemor…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) [Phase 3]
Phase 3 study updating BL-B01D1 vs physician's choice chemotherapy in recurrent or metastatic esophageal squamous cell carcinoma; the trial …
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
A clinical trial update from Fudan University describes evaluating Tpex T-cell subsets in negative tumor-draining lymph nodes to predict how…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors [Phase 1]
Novartis' Phase 1 dose-finding trial of TNO155 in adults with advanced solid tumors has been terminated. No efficacy results are provided in…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating QL1706 in combination with nab-paclitaxel and cisplatin as first-line therapy for advanced or metastatic e…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC [Phase 2]
Phase 2 trial of Vebrekotuzumab with or without an anti-PD-1 antibody for pretreatment advanced esophageal squamous cell carcinoma has been …